Диссертация (1140954), страница 16
Текст из файла (страница 16)
11. – P. 1743–1750.176. Schon M.P. TLR7 and TLR8 as targets in cancer therapy / M.P. Schon, M. Schon// Oncogene. – 2008. – V. 27. – P. 190–199.177. Schreiber R.D. Cancer immunoediting: integrating immunity’s roles in cancersuppression and promotion / R.D. Schreiber, L.J. Old, M.J. Smyth // Science. –2011. – V. 331. – P. 1565–1570.101178.
Sidky Y.A. Inhibition of murine tumor growth by an interferon-inducingimidazoquinolinamine / Y.A. Sidky et al. // Cancer research. – 1992. – V. 52. – P.3528–3533.179. Simonetti O. Potential role of CCL27 and CCR10 expression in melanomaprogression and immune escape / O. Simonetti, G. Goteri, G. Lucarini, A. Filosa,T. Pieramici et al. // Eur. J. Cancer. – 2006. – V. 42(8). – P. 1181–1187180. Singh R. Expression and histopathological correlation of CCR9 and CCL25 inovarian cancer / R. Singh, C.R. Stockard, W.E.
Grizzle, J.W. Lillard, S. Singh //Int. J. Oncol. – 2011. – V. 39(2). – P. 373–381.181. Singh S. CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelialcell proliferation, migration and capillary-like structure formation / S. Singh, S.Wu, M. Varney, A.P. Singh, R.K. Singh // Microvasc. Res.
– 2011. – V. 82(3). –P. 318–325.182. Smith M.C. CXCR4 regulates growth of both primary and metastatic breastcancer / M.C. Smith, K.E. Luker, J.R. Garbow, J.L. Prior, E. Jackson et al. //Cancer Res. – 2004. – V. 64(23). – P. 8604-8612.183. So E.Y. The application of Toll like receptors for cancer therapy / E.Y. So, T.Ouchi // International journal of biological sciences. – 2010. – V. 6. – P. 675–681.184. Sobrino Najul E.J. Chemokine receptor CXCR4-mediated transformation ofmammary epithelial cells by enhancing multiple RTKs expression andderegulation of the p53/MDM2 axis / E.J.
Sobrino Najul, T.A. Toth, C.M. Ng,S.A. Lelievre, M. Fred, C.K. Tang // Cancer Lett. – 2011. – V. 307(2). – P. 132140.185. Song J.K. Deficiency of C-C chemokine receptor 5 suppresses tumordevelopment via inactivation of NF-κB and upregulation of IL-1Ra in melanomamodel / J.K. Song, M.H. Park, D.Y. Choi, H.S. Yoo, S.B. Han et al. // PLoS One.– 2012. – V. 7(5). – P. e33747102186. Speetjens F.M.Nuclear localization of CXCR4 determines prognosis forcolorectal cancer patients / Liefers G.J., Korbee C.J., Mesker W.E., van de VeldeC.J., van Vlierberghe R.L., Morreau H, Tollenaar R.A., Kuppen P.J.
//CancerMicroenviron – 2009 – V 2(1) – P.1–7.187. Starnes CO. Coley’s toxins in perspective // Nature – 1992– V357– P.11–12.188. Steinman R.M. Dendritic cells in the T-cell areas of lymphoid organs / SteinmanR.M Pack M, Inaba K // Immunol. Rev – 1997 – V 156 – P.25–37189.
Strieter R.M. The functional role of the ELR motif in CXC chemokine-mediatedangiogenesis / Strieter R.M, Polverini P.J., Kunkel S.L., Arenberg D.A., BurdickM.D., Kasper J., Dzuiba J., Van Damme J., Walz A., Marriott D., et al. // J. Biol.Chem. – 1995 – V 270(45):27348–27357.190. Su L.
Differential expression of CXCR4 is associated with the metastaticpotential of human non-small cell lung cancer cells / Su L, Zhang J, Xu H, WangY, Chu Y, Liu R, Xiong S // Clin. Cancer Res– 2005– V11(23) – P.8273–8280.191. Sun Y.X.Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers(PCa) in vivo / Sun Y.,Wang J., Shelburne C.E., Lopatin D.E., Chinnaiyan A.M.,Rubin M.A., Pienta K.J., Taichman R.S.
// J. Cell. Biochem – 2003 – V 89(3) –P.462–473.192. Swann J, et al. Demonstration of inflammation-induced cancer and cancerimmunoediting during primary tumorigenesis //Proc Natl Acad Sci U S A – 2008– 105 – P.652–656.193. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer:correlation with lymph node metastasis // Int. J. Cancer – 2003 – V105(2) –P.186–189.194. Takeuchi H.CCL21 chemokine regulates chemokine receptor CCR7 bearingmalignant melanoma cells / Takeuchi H, Fujimoto A, Tanaka M, Yamano T,Hsueh E, Hoon D.S.
// Clin. Cancer Res – 2004 – V.10(7) – P.2351–2358.103195. Teng M.W. Conditional regulatory T-cell depletion releases adaptive immunitypreventing carcinogenesis and suppressing established tumor growth/ Teng M.W,Ngiow S.F., von Scheidt B., McLaughlin N., Sparwasser T., Smyth M.J.// CancerRes. – 2010 – V.70 – P.7800–9.196. Terasaki M.
CXCL12/CXCR4 signaling in malignant brain tumors: a potentialpharmacological therapeutic target/Terasaki M., Sugita Y., Arakawa F., OkadaY., Ohshima K., Shigemori M // Brain Tumor Pathol. – 2011 – V.28(2) – P.89–97.197. Treon SP, et al. MYD88 L265P somatic mutation in Waldenstrom’smacroglobulinemia //The New England journal of medicine. – 2012 – V. 367 – P.826–833.198. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolvingnew concepts // Annu Rev Immunol. – 2012 – V.30 – P.
677–706.199. Tu S, et al. Overexpression of interleukin-1beta induces gastric inflammation andcancer and mobilizes myeloid-derived suppressor cells in mice // Cancer Cell. 2008 – V. 14 – P. 408–419.200. Tye H, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesisindependent of tumor inflammation // Cancer cell.
– 2012 – V. 22 – P. 466–478201. Vacchelli E, et al. Trial watch: FDA-approved Toll-like receptor agonists forcancer therapy // Oncoimmunology. – 2012 – V. 1 – P. 894–907.202. Vesely M.D. Natural innate and adaptive immunity to cancer / Vesely M.D,Kershaw M.H., Schreiber R.D., Smyth M.J. // Annu Rev Immunol. - 2011 V.29 – P. 235–71.203. Villablanca E.J. Tumor-mediated liver X receptor-alpha activation inhibits CCchemokine receptor-7 expression on dendritic cells and dampens antitumorresponses / Villablanca E.J., Raccosta L., Zhou D., Fontana R., Maggioni D.,Negro A., Sanvito F., Ponzoni M., Valentinis B., Bregni M., Prinetti A.,104Steffensen K.R., Sonnino S., Gustafsson J.A., Doglioni C., Bordignon C., et al //Nat.
Med. - 2010 V. - 16(1) – P. 98–105.204. Viola, A. T cells and their partners: the chemokine dating agency / Viola, A.ContentoR.L., Molon B. // Trends Immunol – 2006 – V. 27 – P. 421–427.205. Volk A. Co-inhibition of NF-κB and JNK is synergistic in TNF-expressinghuman AML / Volk A., Li J., Xin J., You D., Zhang J., Liu X., Xiao Y., BreslinP., Li Z., Wei W., Schmidt R., Li X., Zhang Z., Kuo P.C., Nand S., Zhang J.,Chen J., Zhang J/ J Exp Med - 2014 – V.
211(6) – P. 1093–1108206. Wald D, et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1receptor signaling // Nat Immunol. - 2003 – V. 4 – P. 920–927.207. Walser T.C. Antagonism of CXCR3 inhibits lung metastasis in a murine model ofmetastatic breast cancer / Walser T.C., Rifat S., Ma X., Kundu N., Ward C.,Goloubeva O., Johnson M.G., Medina J.C., Collins T.L., Fulton A.M // CancerRes. – 2006 – V. 66(15) – P. 7701–7707.208. Wang J. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediatedinvasive and prosurvival pathways in head and neck cancer cells independent ofEGFR / Wang J., Zhang X., Thomas S.M., Grandis J.R., Wells A., Chen Z.G.,Ferris R.L // Oncogene. – 2005 – V.
24(38) – P. 5897–5904.209. Wani N. C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signalingregulates breast cancer growth and metastasis by modulating the tumormicroenvironment / Wani N., Nasser M.W., Ahirwar D.K., Zhao H., Miao Z.,Shilo K., Ganju R.K // Breast Cancer Res. - 2014 May 29 – V.16(3)210. Weber K. Expression of CCR2 by endothelial cells : implications for MCP-1mediated wound injury repair and In vivo inflammatory activation of endothelium/Weber K., Nelson P.J., Grone H.J., Weber C // Arterioscler.
Thromb. Va c. Biol.– 1999 – V.19(9) – P.2085–2093.105211. Wendel M. Natural killer cell accumulation in tumors is dependent on IFN-γ andCXCR3 ligands / Wendel M., Galani I.E., Suri-Payer E, Cerwenka A // CancerRes. – 2008 – V.68 – P. 8437–45.212. WendtM.K.SilencingofepithelialCXCL12expressionbyDNAhypermethylation promotes colonic carcinoma metastasis / Wendt M.K.,Johanesen P.A., Kang-Decker N., Binion D.G., Shah V., Dwinell M.B //Oncogene.
– 2006 – V.25(36) – P.4986–4997.213. Wendt M.K.Epigenetic silencing of CXCL12 increases the metastatic potential ofmammary carcinoma cells / Wendt M.K.Cooper A.N., Dwinell M.B // Oncogene.- 2008 – V.27(10) – P. 1461–1471.214. West XZ, et al. Oxidative stress induces angiogenesis by activating TLR2 withnovel endogenous ligands // Nature.
- 2010 – V. 467 – P. 972–976.215. Wiley H.E.Expression of CC chemokine receptor-7 and regional lymph nodemetastasis of B16 murine melanoma / Wiley H.E.,Gonzalez E.B., Maki W., WuM.T., Hwang S.T// J. Natl. Cancer Inst. - 2001 – V.93(21) – P. 1638–1643.216. Wu S. Chemokine IL-8 and chemokine receptor CXCR3 and CXCR4 geneexpression in childhood acute lymphoblastic leukemia at first relapse / Wu S.,Gessner R., Taube T., Korte A., von Stackelberg A., Kirchner R., Henze G.,Seeger K. J //Pediatr. Hematol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
